# Gemcitabine Plus Ascorbate for Sarcoma in Adults

> **NCT03468075** · PHASE2 · TERMINATED · sponsor: **Mohammed Milhem, MBBS** · enrollment: 10 (actual)

## Conditions studied

- Sarcoma
- Soft Tissue Sarcoma
- Unresectable Soft Tissue Sarcoma
- Metastatic Bone Tumor
- Bone Sarcoma

## Interventions

- **DRUG:** Ascorbate
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03468075
- **Lead sponsor:** Mohammed Milhem, MBBS
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-11
- **Primary completion:** 2019-04-16
- **Final completion:** 2020-10-19
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Stopping rules met
- **Last updated:** 2020-12-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03468075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03468075, "Gemcitabine Plus Ascorbate for Sarcoma in Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03468075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*